ARA 290, also known as Cibinetide, is a synthetic peptide derived from the structure of erythropoietin (EPO) but engineered to exclude EPO’s hematopoietic, red-blood-cell–stimulating effects [1].
Instead, ARA 290 selectively targets the innate repair receptor (IRR), a heteromeric EPOR/CD131 complex involved in cellular protection, inflammatory resolution, and tissue homeostasis [2].
By isolating the non-erythropoietic region of the EPO molecule, researchers created a peptide that retains EPO’s cytoprotective and pro-repair signaling without impacting hematocrit or erythropoiesis.
As a result, ARA 290 has gained significant attention as a research peptide used to study pathways related to cellular stress, microvascular function, and immune modulation.
ARA 290 has been studied for its influence on nerve integrity and health. Its activity centers on the innate repair receptor (IRR), a heteromeric EPOR/CD131 complex that becomes activated in response to cellular stress [2, 3].
IRR activation has been shown to modulate inflammatory cascades that contribute to neuronal hypersensitivity.
A Phase 2 RCT in adults with type 2 diabetes and painful small-fiber neuropathy evaluated whether ARA 290 can mitigate neuropathic pain [1].
This study followed a parallel timeline, where 48 participants first received ARA 290 4 mg subcutaneously (SC) daily for 28 days, or matched placebo, followed by 28 days of observation.
Results showed that ARA 290:
There were minimal significant adverse events, and no anti–ARA 290 antibodies detected.
These findings support ARA 290 as a potential disease-modifying agent for diabetic small-fiber neuropathy, with benefits extending to widespread metabolic regulation.
Similar neuroprotective effects of ARA290 have been found in models of radiation induced injury and peripheral nerve damage [4, 5].
Beyond its effects on neural pathways, ARA 290 has been investigated for its influence on metabolic and cardiovascular homeostasis through its selective activation of the innate repair receptor (IRR).
A randomized, controlled preclinical trial determined whether ARA290 could affect cardiac aging and function in 48 advanced-age Fischer x Brown Norway rats [6].
Rats were assigned to chronic ARA 290 or saline control from 18-33 months of age.
Results showed that ARA 290 administration:
Long-term administration of ARA290 attenuates multiple hallmarks of cardiac aging. By preserving cardiomyocyte function, ARA290 appears to extend healthspan and mitigate the systemic decline associated with advanced age.
ARA 290 plays a distinct role in immune modulation and tissue recovery through the activation of the IRR pathway, among others.
ARA290 activation influences macrophage polarization, encouraging a shift from pro-inflammatory M1 macrophages toward M2 macrophages that facilitate debris clearance, extracellular matrix organization, and overall tissue restoration [7].
An in vitro preclinical study evaluated whether using an elastin-like peptide (ELP) fusion can increase stability of ARA290 and enhance wound healing in a full-thickness diabetic wound model [8].
After establishing that ELP fusion preserved biological activity, results showed that:
Fusing ARA290 to elastin-like peptide generates stable, proteolytically resistant, bioactive therapeutics suitable for the harsh environment of chronic diabetic wounds.
ARA290 has also shown efficacy in non-diabetic injury models, including ischemic/reperfusion injury in kidney models and surface burns [9, 10]
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). ARA290 is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes five independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 4-panel testing protocol: HPLC purity analysis, ESI-MS identity confirmation, LAL endotoxin screening, and amino acid analysis (for peptides >15 residues). Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders placed before noon PST, Monday–Saturday, ship the same day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and amino acid analysis where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 10+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.